Regencell Bioscience Holdings Limited (RGC)
| Market Cap | 11.75B +325.8% |
| Revenue (ttm) | n/a |
| Net Income | -7.05M |
| EPS | -0.01 |
| Shares Out | 495.47M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 137,977 |
| Open | 24.10 |
| Previous Close | 24.31 |
| Day's Range | 23.09 - 24.27 |
| 52-Week Range | 9.39 - 83.60 |
| Beta | 1.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 8, 2026 |
About RGC
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Full Company ProfileFinancial Performance
Financial StatementsNews
RGC Investors Have Rights – If You Lost Money Investing in Regencell Bioscience Holdings Limited Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings ...
Regencell Bioscience falls -10.7%
Regencell Bioscience (RGC) is down -10.7%, or -$3.31 to $27.52.
Regencell Bioscience falls -7.1%
Regencell Bioscience (RGC) is down -7.1%, or -$2.19 to $28.64.
Regencell Bioscience falls -9.5%
Regencell Bioscience (RGC) is down -9.5%, or -$3.22 to $30.50.
Regencell Bioscience rises 49.5%
Regencell Bioscience (RGC) is up 49.5%, or $12.59 to $38.02.
Regencell Bioscience rises 23.9%
Regencell Bioscience (RGC) is up 23.9%, or $6.07 to $31.50.
Regencell Bioscience files to sell ordinary shares, no amount given
06:16 EDT Regencell Bioscience (RGC) files to sell ordinary shares, no amount given
Regencell Bioscience falls -8.7%
Regencell Bioscience (RGC) is down -8.7%, or -$2.37 to $25.00.
Regencell Bioscience rises 15.4%
Regencell Bioscience (RGC) is up 15.4%, or $3.53 to $26.50.
Regencell Bioscience rises 26.7%
Regencell Bioscience (RGC) is up 26.7%, or $6.14 to $29.11.
Regencell Bioscience Holdings Ltd trading resumes
11:10 EDT Regencell Bioscience (RGC) Holdings Ltd trading resumes
Regencell Bioscience Holdings Ltd trading halted, volatility trading pause
11:05 EDT Regencell Bioscience (RGC) Holdings Ltd trading halted, volatility trading pause
Regencell Bioscience falls -7.9%
Regencell Bioscience (RGC) is down -7.9%, or -$1.85 to $21.50.
Regencell Bioscience rises 18.2%
Regencell Bioscience (RGC) is up 18.2%, or $5.28 to $34.30.
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Regencell Bioscience Holdings Ltd (RGC) 192.53% +2.91, Columbus Circle Capital Corporation I (BRR) 20....
Regencell Bioscience rises 11.6%
Regencell Bioscience (RGC) is up 11.6%, or $2.90 to $27.89.
Regencell Bioscience rises 15.4%
Regencell Bioscience (RGC) is up 15.4%, or $4.49 to $33.69.
Regencell Bioscience deals with struggling business, yet shares surge, WSJ says
Regencell Bioscience (RGC) is dealing with a struggling business and Justice Department investigation, yet shares have been surging, Jonathan Weil of The Wall Street Journal reports. The company claim...
This $14 Billion Meme Stock Says It Is Developing a Herbal Remedy for Autism
The Nasdaq-listed company has recurring losses and no revenue.
Regencell Bioscience falls -10.9%
Regencell Bioscience (RGC) is down -10.9%, or -$3.41 to $28.00.
Regencell Bioscience rises 15.0%
Regencell Bioscience (RGC) is up 15.0%, or $4.63 to $35.40.
Regencell Bioscience Holdings Annual report: Q4 2025
Regencell Bioscience Holdings has published its Q4 2025 annual report on October 31, 2025.
This stock with no revenue surges 64,000% in a year: find out why
Regencell Bioscience Holdings, a biotech company focused on herbal medicine, has gained over 400% on Monday and over 64,000% in the past year. This growth in stock price is despite the company not hav...
Regencell Bioscience Holdings Annual report: Q4 2024
Regencell Bioscience Holdings has published its Q4 2024 annual report on October 25, 2024.
Regencell Bioscience Holdings Annual report: Q4 2023
Regencell Bioscience Holdings has published its Q4 2023 annual report on October 27, 2023.